This study explores the implications of measurable residual disease progression (MRD-P) in patients with newly diagnosed multiple myeloma (NDMM) treated with quadruplet therapy (QUAD) and autologous stem cell transplantation (ASCT). The research highlights how MRD-P, defined as a quantitative increase in MRD burden without meeting traditional progression criteria, impacts treatment decisions and patient outcomes. 

Key Points:

• Measurable residual disease (MRD) progression (MRD-P) in NDMM patients under QUAD + ASCT indicates impending disease progression, challenging current paradigms of treatment response assessment.
• Patients experiencing MRD-P often exhibit high-risk genetic abnormalities and poorer clinical outcomes, comparable to those with conventionally defined disease progression.
• Therapy modification upon MRD-P detection frequently involves monoclonal antibody-based regimens, yet subsequent progression-free survival remains a critical concern.
• The study underscores the need for reevaluating treatment strategies based on MRD dynamics rather than solely relying on traditional progression markers.

Authors:
Luciano J. Costa, MD, PhD; Eva Medvedova, MD; Binod Dhakal, MBBS; Bhagirathbhai R. Dholaria, MBBS; Smith Giri; Saurabh Chhabra, MD; Susan Bal, MD; Kelly Godby; Gayathri Ravi, MD; Rebecca W. Silbermann; Natalie Callander, MD